Suppr超能文献

肥胖症药物治疗:下一步是什么?

Obesity pharmacotherapy: what is next?

机构信息

Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, United States.

出版信息

Mol Aspects Med. 2013 Feb;34(1):71-83. doi: 10.1016/j.mam.2012.10.005. Epub 2012 Oct 24.

Abstract

The increase in obesity in the Unites States and around the world in the last decade is overwhelming. The number of overweight adults in the world surpassed 1 billion in 2008. Health hazards associated with obesity are serious and include heart disease, sleep apnea, diabetes, and cancer. Although lifestyle modifications are the most straightforward way to control weight, a large portion of the population may not be able to rely on this modality alone. Thus, the development of anti-obesity therapeutics represents a major unmet medical need. Historically, anti-obesity pharmacotherapies have been unsafe and minimally efficacious. A better understanding of the biology of appetite and metabolism provides an opportunity to develop drugs that may offer safer and more effective alternatives for weight management. This review discusses drugs that are currently on the market and in development as anti-obesity therapeutics based on their target and mechanism of action. It should serve as a roadmap to establish expectations for the near future for anti-obesity drug development.

摘要

在过去十年中,美国和全球的肥胖人口呈压倒性增长。2008 年,全球超重成年人的数量超过 10 亿。肥胖相关的健康危害非常严重,包括心脏病、睡眠呼吸暂停、糖尿病和癌症。尽管生活方式的改变是控制体重最直接的方法,但很大一部分人可能无法仅依赖这种方法。因此,开发抗肥胖治疗药物代表着一个重大的未满足的医疗需求。从历史上看,抗肥胖药物治疗不安全且效果有限。对食欲和代谢生物学的更好理解为开发可能为体重管理提供更安全、更有效的替代药物提供了机会。本文综述了目前市场上和正在开发中的抗肥胖治疗药物,根据其作用靶点和作用机制进行分类。它应该为未来的抗肥胖药物开发建立一个预期的路线图。

相似文献

1
Obesity pharmacotherapy: what is next?
Mol Aspects Med. 2013 Feb;34(1):71-83. doi: 10.1016/j.mam.2012.10.005. Epub 2012 Oct 24.
2
New advances in models and strategies for developing anti-obesity drugs.
Expert Opin Drug Discov. 2013 Jun;8(6):655-71. doi: 10.1517/17460441.2013.792804. Epub 2013 Apr 29.
4
Central and peripheral molecular targets for antiobesity pharmacotherapy.
Clin Pharmacol Ther. 2010 Jun;87(6):652-62. doi: 10.1038/clpt.2010.57. Epub 2010 May 5.
5
Pharmacotherapy of Obesity: Limits and Perspectives.
Am J Cardiovasc Drugs. 2019 Aug;19(4):349-364. doi: 10.1007/s40256-019-00328-6.
6
Current and Future Medical Treatment of Obesity.
Gastrointest Endosc Clin N Am. 2017 Apr;27(2):181-190. doi: 10.1016/j.giec.2016.12.008.
8
[The pharmacotherapy of obesity].
Acta Pharm Hung. 2015;85(1):3-17.
9
Current pharmacotherapeutic concepts for the treatment of obesity in adults.
Ther Adv Cardiovasc Dis. 2009 Feb;3(1):75-90. doi: 10.1177/1753944708098226. Epub 2008 Nov 28.
10
Current pharmacotherapy for obesity.
Nat Rev Endocrinol. 2018 Jan;14(1):12-24. doi: 10.1038/nrendo.2017.122. Epub 2017 Oct 13.

引用本文的文献

1
Detection of natural autoimmunity to ghrelin in diabetes mellitus.
Front Med Technol. 2024 Jul 12;6:1407409. doi: 10.3389/fmedt.2024.1407409. eCollection 2024.
3
Pharmacophore-based virtual screening from phytocannabinoids as antagonist r-CB1.
J Mol Model. 2022 Aug 17;28(9):258. doi: 10.1007/s00894-022-05219-3.
4
The genus Rumex (Polygonaceae): an ethnobotanical, phytochemical and pharmacological review.
Nat Prod Bioprospect. 2022 Jun 16;12(1):21. doi: 10.1007/s13659-022-00346-z.
6
Histamine H Receptor Ligands-KSK-59 and KSK-73-Reduce Body Weight Gain in a Rat Model of Excessive Eating.
Pharmaceuticals (Basel). 2021 Oct 25;14(11):1080. doi: 10.3390/ph14111080.
7
Targeting Energy Expenditure-Drugs for Obesity Treatment.
Pharmaceuticals (Basel). 2021 May 6;14(5):435. doi: 10.3390/ph14050435.
8
Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.
Future Med Chem. 2020 Oct;12(20):1865-1884. doi: 10.4155/fmc-2019-0361. Epub 2020 Oct 12.
9
Insights on Obesity in Children and Adults: Individualizing Management.
Trends Endocrinol Metab. 2019 Oct;30(10):724-734. doi: 10.1016/j.tem.2019.07.016. Epub 2019 Aug 6.
10
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
Curr Obes Rep. 2018 Jun;7(2):147-161. doi: 10.1007/s13679-018-0300-4.

本文引用的文献

1
Orlistat and acute kidney injury: an analysis of 953 patients.
Arch Intern Med. 2011 Apr 11;171(7):703-4. doi: 10.1001/archinternmed.2011.103.
2
Enhanced striatal dopamine release during food stimulation in binge eating disorder.
Obesity (Silver Spring). 2011 Aug;19(8):1601-8. doi: 10.1038/oby.2011.27. Epub 2011 Feb 24.
3
A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity.
Eur J Pharmacol. 2011 Jan 15;650(2-3):663-72. doi: 10.1016/j.ejphar.2010.10.040. Epub 2010 Oct 29.
4
Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.
Am J Clin Nutr. 2010 Oct;92(4):810-7. doi: 10.3945/ajcn.2010.29663. Epub 2010 Aug 18.
8
The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.
Endocr Rev. 2010 Aug;31(4):506-43. doi: 10.1210/er.2009-0037. Epub 2010 Feb 26.
9
Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery.
Trends Endocrinol Metab. 2010 Jun;21(6):337-44. doi: 10.1016/j.tem.2010.01.006. Epub 2010 Feb 3.
10
Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity.
Obesity (Silver Spring). 2010 Dec;18(12):2241-6. doi: 10.1038/oby.2009.503. Epub 2010 Jan 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验